유형균
유형균 교수
전공임상약리학
연락처
hgyoo0317@cha.ac.kr
학력
- 2002 - 2006 Seoul National University (B.S.)
- 2010 - 2014 CHA University (M.D.)
- 2017 – 2022 Seoul National University (Ph.D.)
경력
- 2016 – 2020 서울대학교병원 임상약리학과 연수의사
- 2020 – 2020 서울대학교병원 임상약리학과 연구임상강사
- 2020 – 2021 차 의과학대학교 분당차병원 임상강사
- 2021 – 2022 차 의과학대학교 분당차병원 임상연구조교수
- 2022 – 2023 차 의과학대학교 분당차병원 임상조교수
- 2023 – 2023 차 의과학대학교 의학전문대학원 임상약리학교실 조교수
- 2023~ 차 의과학대학교 분당차병원 조교수 /차 의과학대학교 의학전문대학원 약리학교실 조교수
논문
- 7-1. Yang, A. Y., Yoo, H., Shin, W., Lee, Y. S., Lee, H., Kim, S. E., & Kim, A. (2023). Size-reduced fexuprazan 20 mg demonstrated the optimal bioavailability and bioequivalence with the reference formulation. Translational and Clinical Pharmacology, 31(1), 40.
- 7-2. Yoo, H., Shin, W., Lee, B., Park, J., Lee, Y., & Kim, A. (2024). Pharmacokinetics and Food Effect Between a 100‐mg Sustained‐Release Tablet and a 50‐mg Immediate‐Release Tablet of Vildagliptin in Healthy Subjects. Clinical Pharmacology in Drug Development, 13(2), 122-127.
- 7-3. Shin, W., Yang, A. Y., Park, H., Lee, H., Yoo, H., & Kim, A. (2023). A Comparative Pharmacokinetic Study of Fexuprazan 10 mg: Demonstrating Bioequivalence with the Reference Formulation and Evaluating Steady State. Pharmaceuticals, 16(8), 1141.
- 7-4. Shin, W., Yang, A. Y., Yoo, H., & Kim, A. (2023). Drug–Drug Interactions between Tamsulosin and Mirabegron in Healthy Individuals Do Not Affect Pharmacokinetics and Hemodynamic Parameters Significantly. Pharmaceuticals, 16(10), 1457.
- 7-5. Shin, W., Park, M. Y., Kim, J., Kim, J., Nam, J. H., Choi, J., ... & Kim, A. (2024). No drug–drug interactions between selective prolyl‐tRNA synthetase inhibitor, bersiporocin, and pirfenidone or nintedanib in healthy participants. Clinical and Translational Science, 17(1), e13701.
- 7-6. Park, M., Choi, S., Han, S., Shin, W., Kim, A., Han, S., ... & Yoo, H. (2023). Pharmacokinetic properties of a new sustained-release pregabalin tablet in subjects with reduced renal function. Translational and Clinical Pharmacology, 31(4), 226.
- 7-7. Kim, A., Hong, J. H., Shin, W., Yoo, H., Jung, J. G., Reginster, J. Y., ... & Silverman, S. (2024). A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Expert Opinion on Biological Therapy, 1-9.
- 7-8. Shin, W., Lee, D. H., Yoo, H., Jung, H., Bang, M., & Kim, A. (2024). Assessing the Clinical Efficacy of Therapeutic Drug Monitoring for Risperidone and Paliperidone in Patients with Schizophrenia: Insights from a Clinical Data Warehouse. Pharmaceuticals, 17(7), 882.